RESELIGO 10.8mg x 1 implant

RESELIGO 10.8mg x 1 implant

RESELIGO is indicated (see also section 5.1): - In the treatment of metastatic prostate cancer, where goserelin has shown comparable survival benefits to surgical castration (see section 5.1). - In the treatment of locally advanced prostate cancer, as an alternative to surgical castration, where goserelin has shown comparable survival benefits to antiandrogen therapy (see section 5.1). - As adjuvant therapy to radiotherapy in patients with localised or locally advanced prostate cancer at high risk of disease progression, where goserelin has shown improved disease-free survival and overall survival (see section 5.1). - As neoadjuvant therapy before radiotherapy in patients with localised or locally advanced prostate cancer at high risk of disease progression, where goserelin has shown improved disease-free survival (see section 5.1). - As adjuvant therapy to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression, where goserelin has been shown to improve disease-free survival (see section 5.1).Goserelin (as acetate)